Transverse Medical, Inc., developer of the POINT-GUARD™ Dynamic Cerebral Embolic Protection (CEP) device to protect the patient from stroke during Transcatheter Aortic Valve Replacement (TAVR), is pleased to announce the appointment of experienced life sciences professional, board director, former chief financial executive, and consultant, Mr. David K. Stone, as non-executive independent Director member of the Board.
GOLDEN, COLO. (PRWEB) FEBRUARY 19, 2020
David is a Colorado native residing in Elbert, Colorado. A graduate of Colorado State University and Harvard Business School, he is a former executive, consultant and investment banker focused on private life sciences companies. He has over 30 years of experience as a project manager, communications director, sell-side analyst, venture capitalist and consultant. Prior to joining the Board of Directors with Transverse Medical, Mr. Stone served as a Board member with both private and public companies, and held CFO Executive positions with Cytrellis Biosystems, Inc., Gen9, Inc and Frequency Therapeutics.
Eric Goslau, TMI CEO, commented that “David’s particular focus on corporate strategy and positioning, communications, raising capital, mergers and acquisitions will be instrumental, as TMI completes key steps towards the next clinical in-human study milestone during 2020 and seeks strategic relationships with major TAVR valve manufacturers in a US market projected to be $4.8 billion by 2025. Stroke is viewed and accepted as unpredictable during TAVR procedures. Point-Guard’s unique and innovative design will offer maximum coverage of the great aortic arch vessels for protection of the brain from embolic debris, by addressing the majority of aortic anatomical challenges encountered during TAVR.”
David remarked “It is a pleasure to join Transverse, as it develops a solution for CEP during TAVR. Clinical Stroke is especially worrisome as a devastating, costly and major complication, now that TAVR is moving from high risk to intermediate and low risk patients. Our Clinical Steering Committee of internationally known physicians from the Cleveland Clinic, Houston Methodist and Dresden Medical Center in Germany are firm in their belief and commitment that even one disabling stroke is one too many.”
About Transverse Medical Inc
Transverse Medical, with Corporate Headquarters in Golden, Colorado develops the POINT-GUARD™ Cerebral Embolic Protection System for use during Transcatheter Aortic Valve Replacements to protect patients from embolic debris (particles) that could lead to periprocedural stroke as a result of the TAVR procedure. The company is preparing for clinical trials with a feasibility study of their next generation Point-Guard device planned for 2H2020; the FDA Trial will follow upon successful completion of the feasibility study and confirmation of the next generation Point-Guard in-human. The next generation Point-Guard is a breakthrough advancement for Cerebral Embolic Protection of the brain and designed with operator ease of use and ability to accommodate variable arch anatomies with low interference and full aortic arch stabilization. Additional information is available at:
Notice: The Point-Guard™ is currently in development and has not been approved for human use by the US FDA or any regulatory authority.